Published in Neuroendocrinology on August 24, 2006
Progesterone exerts neuroprotective effects after brain injury. Brain Res Rev (2007) 1.54
Endogenous opiates and behavior: 2006. Peptides (2007) 0.92
Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia. Schizophr Bull (2008) 0.91
Progesterone and medroxyprogesterone acetate differentially regulate alpha4 subunit expression of GABA(A) receptors in the CA1 hippocampus of female rats. Physiol Behav (2009) 0.88
Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase. Psychoneuroendocrinology (2014) 0.82
Medroxyprogesterone acetate is associated with increased sleep spindles during non-rapid eye movement sleep in women referred for polysomnography. Psychoneuroendocrinology (2013) 0.80
Progesterone facilitates exploration, affective and social behaviors among wildtype, but not 5α-reductase Type 1 mutant, mice. Behav Brain Res (2013) 0.80
Changes in stress-stimulated allopregnanolone levels induced by neonatal estradiol treatment are associated with enhanced dopamine release in adult female rats: reversal by progesterone administration. Psychopharmacology (Berl) (2016) 0.75
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Estrogen, cognition and female ageing. Hum Reprod Update (2006) 1.78
The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol (2007) 1.61
Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril (2002) 1.45
The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol (2007) 1.40
Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother (2004) 1.30
Genomic and non-genomic effects of estrogens on endothelial cells. Steroids (2004) 1.20
Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One (2008) 1.14
Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol (2010) 1.12
Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol (2005) 1.12
Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm. J Endocrinol (2008) 1.08
New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas (2005) 1.03
Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res (2009) 1.01
Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol (2007) 1.01
Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol (2008) 1.01
Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas (2008) 1.00
Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol (2006) 1.00
Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynecol Endocrinol (2012) 1.00
Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol (2005) 0.98
Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology (2010) 0.98
Compensatory feto-placental upregulation of the nitric oxide system during fetal growth restriction. PLoS One (2012) 0.95
Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol (2009) 0.95
Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gynecol Endocrinol (2008) 0.94
Endocrinology of menopausal transition and its brain implications. CNS Spectr (2005) 0.93
Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. Gynecol Endocrinol (2006) 0.93
The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol (2004) 0.92
Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations. Gynecol Endocrinol (2008) 0.90
Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol (2005) 0.90
Conjugated equine estrogens reverse the effects of aging on central and peripheral allopregnanolone and beta-endorphin levels in female rats. Fertil Steril (2004) 0.90
Spontaneous cornual pregnancy after homolateral salpingectomy for an earlier tubal pregnancy: a case report and literature review. J Minim Invasive Gynecol (2009) 0.89
Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol (2006) 0.88
Follicular fluid VEGF levels directly correlate with perifollicular blood flow in normoresponder patients undergoing IVF. J Assist Reprod Genet (2008) 0.88
Female infertility related to thyroid autoimmunity: the ovarian follicle hypothesis. Am J Reprod Immunol (2011) 0.88
Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer (2008) 0.87
Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J Agric Food Chem (2008) 0.87
Oestrogen and progestins differently prevent glutamate toxicity in cortical neurons depending on prior hormonal exposure via the induction of neural nitric oxide synthase. Steroids (2009) 0.86
Rapid estrogen actions in the cardiovascular system. Ann N Y Acad Sci (2006) 0.86
Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF. Hum Fertil (Camb) (2009) 0.86
Long-term low-dose oral administration of dehydroepiandrosterone modulates adrenal response to adrenocorticotropic hormone in early and late postmenopausal women. Gynecol Endocrinol (2006) 0.85
Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gynecol Oncol (2007) 0.85
Estrogen regulates endometrial cell cytoskeletal remodeling and motility via focal adhesion kinase. Fertil Steril (2010) 0.85
Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy. Anticancer Res (2010) 0.85
Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology (2002) 0.84
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril (2010) 0.84
Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol (2006) 0.84
Chromosomal abnormalities in women with premature ovarian failure. Gynecol Endocrinol (2010) 0.84
Endometriosis-Associated Abdominal Wall Cancer: A Poor Prognosis? Int J Gynecol Cancer (2015) 0.84
Timing is everything. Gynecol Endocrinol (2007) 0.84
Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas (2007) 0.83
The perioperative management of patients with gynaecological cancer undergoing major surgery: A debated clinical challenge. Crit Rev Oncol Hematol (2009) 0.83
Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril (2003) 0.83
Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res (2006) 0.83
Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol (2005) 0.83
Allopregnanolone serum levels and expression of 5 alpha-reductase and 3 alpha-hydroxysteroid dehydrogenase isoforms in hippocampal and temporal cortex of patients with epilepsy. Epilepsy Res (2003) 0.83
Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure. Anticancer Res (2011) 0.83
Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton. J Cell Mol Med (2009) 0.82
Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. Gynecol Endocrinol (2009) 0.82
Effect of dehydroepiandrosterone on central and peripheral levels of allopregnanolone and beta-endorphin. Fertil Steril (2005) 0.81
Sexual hormone serum levels and temporomandibular disorders. A preliminary study. Gynecol Endocrinol (2005) 0.81
Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. Anticancer Res (2004) 0.81
Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit Rev Oncol Hematol (2010) 0.81
Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecol Endocrinol (2010) 0.81
Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects. Eur J Endocrinol (2002) 0.81
Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res (2003) 0.81
Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. Crit Rev Oncol Hematol (2011) 0.81
The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol (2009) 0.81
Estrogen receptor-{alpha} promotes endothelial cell motility through focal adhesion kinase. Mol Hum Reprod (2010) 0.80
Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol (2007) 0.80
Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity. Psychoneuroendocrinology (2010) 0.80
Androgens and the brain. Maturitas (2007) 0.80
Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol Endocrinol (2006) 0.80
Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature. Anticancer Res (2008) 0.80
Effect of tibolone administration on central and peripheral levels of allopregnanolone and beta-endorphin in female rats. Menopause (2006) 0.80
In vitro effects of progesterone and progestins on vascular cells. Steroids (2003) 0.80
Effects of phytoestrogens derived from red clover on atherogenic adhesion molecules in human endothelial cells. Menopause (2008) 0.80
Circulating levels of neuroactive steroids in patients with binge eating disorder: a comparison with nonobese healthy controls and non-binge eating obese subjects. Int J Eat Disord (2003) 0.80